BI Weekend: Oracle, Kohl’s Earnings, CERAWeek
Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Investor's Business Daily on MSN10h
Stock Market Correction: Trump Tariffs Triggers Sell-Off Despite Tame Inflation: Weekly Review
The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.
Clinical Pain Advisor10h
REDEFINE 2: Significant Weight Loss Observed With CagriSema vs Placebo in Patients With T2D
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Medical Dialogues15h
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...